Search results
Results From The WOW.Com Content Network
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -86.67% and 3.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the ...
This month, we saw the Akebia Therapeutics, Inc. (NASDAQ:AKBA) up an impressive 45%. But that can't change the reality...
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -36.36% and 19.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA): Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the...
Arachidonate 5-lipoxygenase inhibitors are compounds that slow or stop the action of the arachidonate 5-lipoxygenase (5-lipoxygenase or 5-LOX) enzyme, which is responsible for the production of inflammatory leukotrienes.
Akbank was founded in Adana, Turkey in January 1948, originally to provide financing for the cotton producers in the Çukurova region. As the majority of the bank founders were born in the city of Kayseri, the name "Adana-Kayseri Bankası" was chosen, soon to be shortened to its initials AK or Akbank. [6]
Beta-boswellic acid, keto-beta-boswellic acid, and acetyl-keto-beta-boswellic acid (AKBA) have been indicated in apoptosis of cancer cells, in particular brain tumors and cells affected by leukemia or colon cancer. [5] Acetyl-boswellic acids also exhibit anti-inflammatory behaviour by inhibiting leukotriene synthesis. [6]
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.